10-Q: PetVivo Holdings Reports Q1 2025 Results Amidst Nasdaq Delisting

PetVivo Holdings reported a net loss of $2.047 million for the quarter ended June 30, 2024, while navigating a delisting from the Nasdaq stock market.

Summary

• PetVivo Holdings, Inc. reported a net loss of $2.047 million for the three months ended June 30, 2024, compared to a net loss of $2.894 million for the same period in 2023.
• The company's revenue increased slightly to $123,751 from $117,183 year-over-year.
• Operating expenses decreased to $2.155 million from $2.998 million, primarily due to reduced sales and marketing and general and administrative costs.
• The company's cash and cash equivalents decreased to $12,414 from $87,403 at the end of the previous quarter.
• PetVivo's working capital deficit was $211,116 as of June 30, 2024.
• The company issued 2,846,232 shares of common stock during the quarter for proceeds, debt conversion, and services.
• PetVivo's stock was suspended from trading on Nasdaq on April 5, 2024, and the company expects a formal delisting following the expiration of all review periods.

Sentiment

Score: 3

Explanation: The document indicates a struggling company with a significant net loss, a very low cash position, and an impending delisting from Nasdaq. While there are some positive signs of cost reduction, the overall outlook is negative due to the financial instability and delisting.

Positives

• The company's net loss decreased year-over-year, indicating improved cost management.
• Operating expenses were significantly reduced, contributing to the lower net loss.
• The company successfully raised capital through the sale of common stock and convertible notes.
• Revenue saw a slight increase compared to the same period last year.

Negatives

• The company experienced a significant decrease in cash and cash equivalents.
• PetVivo's working capital deficit was $211,116 as of June 30, 2024.
• The company's securities were suspended from trading on Nasdaq and are expected to be delisted.
• The company continues to operate at a loss, raising concerns about its long-term financial sustainability.

Risks

• The company's ability to continue as a going concern is dependent on its ability to achieve profitability and/or obtain adequate financing.
• The delisting from Nasdaq could negatively impact the company's ability to raise capital and its stock price.
• The company has a working capital deficit, indicating potential liquidity issues.
• The company's continued losses from operations raise concerns about its long-term financial viability.
• There is no guarantee that the company will be successful in its ability to raise additional capital to fund its business plan.

Future Outlook

The company expects to continue to raise additional capital through the sale of its securities to fund its business expansion. The company believes the proceeds from a recent private placement offering are sufficient to fund operations for the next three months. The company anticipates a formal delisting from Nasdaq following the expiration of all review periods.

Management Comments

• Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern.
• Management believes that the increased revenues and margins provided by Spryng will accelerate its adoption rate and propel it forward as the standard of care for canine and equine lameness related to or due to synovial joint issues.

Industry Context

The company operates in the veterinary medical device market, specifically targeting osteoarthritis in dogs and horses. The market is characterized by a need for effective treatments that address the underlying causes of joint issues, rather than just the symptoms. PetVivo's product, Spryng, aims to fill this gap by providing a biocompatible solution that reinforces cartilage and improves joint function. The company is competing with traditional treatments such as NSAIDs, steroid injections, and hyaluronic acid injections.

Comparison to Industry Standards

• PetVivo's revenue of $123,751 is relatively low compared to established veterinary pharmaceutical and medical device companies, which often report revenues in the millions or billions of dollars per quarter.
• The company's net loss of $2.047 million is significant, and many established companies in the sector are profitable or have much smaller losses.
• PetVivo's cash position of $12,414 is very low compared to industry standards, where companies typically maintain a much larger cash reserve to fund operations and growth.
• The company's delisting from Nasdaq is a major setback, as most publicly traded companies in the sector maintain their listing on major exchanges.
• Compared to companies like Zoetis or Elanco, which have established distribution networks and a wide range of products, PetVivo is still in the early stages of commercialization with a single product, Spryng.

Management Changes

Legal Proceedings

• The company may become involved in legal proceedings from time to time, but does not anticipate any material adverse effects.

Stakeholder Impact

• Shareholders are negatively impacted by the delisting from Nasdaq and the company's financial losses.
• Employees may be affected by the cost reduction program, including salary reductions for executive officers.
• Customers may be impacted by the company's ability to continue operations and supply products.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• The company will continue to focus on commercializing Spryng and expanding its distribution network.
• The company will seek to raise additional capital to fund its operations and growth.
• The company will navigate the delisting process from Nasdaq.
• The company will continue to develop its pipeline of therapeutic devices.

Key Dates

Keywords

PetVivo, Spryng, Veterinary, Biomaterials, Delisting, Nasdaq, Financial Results, Osteoarthritis, Medical Device, Capital Raise